Navidea Biopharma (NAVB) Misses Q3 EPS by 1c

Navidea Biopharma (NYSE: NAVB) reported Q3 EPS of ($0.05), $0.01 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $3.98 million versus the consensus estimate of $2.78 million.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• TaiMed Biologics gets TFDA drug license notice for HIV therapy Trogarzo
• Atoss Software (AOF:GR) PT Lowered to EUR135 at Berenberg